Minerva Neurosciences Q2 net income of $17.5 million on warrant gain; cash $75.4 million
Minerva Neurosciences reported second quarter 2026 results, showing GAAP net income of $17.5 million, driven by a $27.6 million non-cash gain on its warrant liability. Adjusted net loss widened to $7.8 million from $3.0 million a year earlier, and cash, equivalents and marketable securities fell to $75.4 million from $82.4 million at December 31, 2025, so shareholders face higher operating costs ahead of the confirmatory Phase 3 trial's topline data in the second half of 2027.
Key points
- Q2 2026 GAAP net income was $17.5 million, or $0.36 per basic share, versus a net loss of $3.3 million a year earlier.
- Six-month GAAP net loss was $107.9 million, or $2.38 per share, including an $81.8 million non-cash warrant liability loss.
- R&D expense rose to $7.2 million in Q2 from $1.3 million, mainly due to the C19 trial; G&A rose to $3.5 million from $2.1 million.
- Confirmatory Phase 3 C19 trial is designed to enroll 380 patients, with Phase A topline data expected in 2H 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.